

# pCODR Patient Advocacy Group Conflict of Interest Declarations

## Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. Patient advocacy groups must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency – it does not negate or preclude the use of the patient advocacy group input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

### Section A: Payment Received

1. Has this patient advocacy group received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?

- Yes
- No

If no, please go to Section B

2. What form of payment did this patient advocacy group receive? (Check all that apply.)

- Operating Funds
- Royalties
- Gifts
- Honoraria
- Program Funding (e.g., website)
- Research/educational grants
- Sponsorship of Events
- Other, please specify:

3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

<i>Corporate Funding Sponsors (Healthcare Industry Only)</i> <sup>(1)</sup>	<i>2011</i>	<i>2012YTD</i>
AVEO Pharmaceuticals	\$ [REDACTED]	\$ [REDACTED]
Bayer Healthcare	\$ [REDACTED]	\$ [REDACTED]
GlaxoSmithKline	\$ [REDACTED]	\$ [REDACTED]
Novartis Canada	\$ [REDACTED]	\$ [REDACTED]
Pfizer Oncology	\$ [REDACTED] <sup>(1)</sup>	\$ [REDACTED]
Rx&D	\$ [REDACTED]	\$ [REDACTED]
<i>Total Healthcare Industry Funding</i> <sup>(2)</sup>	\$ [REDACTED]	\$ [REDACTED]
<i>All Other Funding Sources</i>	<i>2011</i>	<i>2012YTD</i>

<sup>(1)</sup> Included one-time funding of \$ [REDACTED] for research grant in kidney cancer survivorship.

Federal or Provincial Funding available to patient organizations		
Number of individual grassroots donors (patients/caregivers/families and healthcare professionals)		
Total charitable donations raised from individuals	\$	\$
Number of Individual donors above \$5,000		
Total charitable donations raised from foundations		\$
Total charitable donations raised by corporate donors (non-healthcare)	\$	\$
Charitable donations raised by Third Party Events, fundraisers	\$	\$
Charitable donations transferred through United Way	\$	\$
Research funding match from CIHR (Small Health Organizations Partnership Program-SHOPP) <sup>(3)</sup>	\$	\$
<b>Total Non-Healthcare Industry Funding <sup>(4)</sup></b>	\$	\$
<b><i>Economic Valuation of Dedicated &amp; Tracked Volunteer Hours (Non-Cash Resources)</i></b>	<b>2011</b>	<b>2012YTD</b>
Economic Valuation of Dedicated and Tracked Volunteer Hours 2011: 37,000 hours(75% management/25% admin) 2012: 23,000 hours YTD (75% management/25% admin) *Valued according to Imagine Canada per: <a href="http://volunteercalculator.imaginecanada.ca/eng">http://volunteercalculator.imaginecanada.ca/eng</a>	\$ * estimated economic valuation	\$ * estimated economic valuation
Number of members (patients/caregivers/healthcare industry members) registered for support and information about kidney cancer		

<sup>(2)</sup> Kidney Cancer Canada has adopted the Canadian Cancer Action Network (CCAN) CCAN Code of Conduct Governing Corporate Funding. The Code is “intended to minimize the impact of real, potential or perceived conflict of interest that may arise when patient organizations accept financial support from companies” and is posted on our website at this address:

<http://www.kidneycancerCanada.ca/main.php?p=12&action=&d=&page=2&s=>



<sup>(3)</sup> “The mandate of the Small Health Organizations Partnership Program (SHOPP) is to foster partnership opportunities with small health charities and not-for-profit organizations with modest health research funding capacity. CIHR, through SHOPP, matches the amount contributed by Kidney Cancer Canada to research under our funding agreement.

<sup>(4)</sup> Kidney Cancer Canada has adopted the Imagine Canada Code of Ethical Fundraising to uphold high standards of accountability and transparency and posted on our website at this address [www.kidneycancerCanada.ca](http://www.kidneycancerCanada.ca) For more information on the Imagine Canada Code see: <http://www.imaginecanada.ca/en/node/21>

**Section B: Holdings or Other Interests**

Has this patient advocacy group received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

No member of the Kidney Cancer Canada Board of Directors is in possession of such stocks or options for organizations that may have a direct or indirect interest in the drug under review. As an organization, Kidney Cancer Canada owns no stocks or options.

**Section C: Affiliations, personal or commercial relationships**

Does this patient advocacy group have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

No member of the Kidney Cancer Canada Board of Directors has personal or commercial relationships of the nature stated above.

Similarly, no member of Kidney Cancer Canada's Board of Directors has personal or influential relationships with provincial cancer agencies, reimbursement agencies, or other government agencies that may have a direct financial interest in the drug under review.

I hereby certify that I have authority to disclose all relevant information with respect to any matter involving this patient advocacy group with a company, organization or entity that may place this patient advocacy group in a real, potential or perceived conflict of interest situation.

Date: August 29, 2012 Name: Deb Maskens

Signature:

